Article
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.
JCI insight - 9 Mar 2017
Gilbert-Ross Melissa, Konen Jessica, Koo Junghui, Shupe John, Robinson Brian S, Wiles Walter Guy, Huang Chunzi, Martin W David, Behera Madhusmita, Smith Geoffrey H, Hill Charles E, Rossi Michael R, Sica Gabriel L, Rupji Manali, Chen Zhengjia, Kowalski Jeanne, Kasinski Andrea L, Ramalingam Suresh S, Fu Haian, Khuri Fadlo R, Zhou Wei, Marcus Adam I
Abstract excerpt
Loss of LKB1 activity is prevalent in KRAS mutant lung adenocarcinoma and promotes aggressive and treatment-resistant tumors. Previous studies have shown that LKB1 is a negative regulator of the focal adhesion kinase (FAK), but in vivo studies testing the efficacy of FAK inhibition in LKB1 mutant cancers are lacking. Here, we took a pharmacologic approach to show that FAK inhibition is an effective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.